4SC - Clinical Study Presentations at the 31. German Conference of Skin Cancer (31. Hautkrebskongress)
* MERKLIN1: Trial in progress e-poster (ID 123) and oral presentation entitled "A phase II, open label, multicenter stud…
* MERKLIN1: Trial in progress e-poster (ID 123) and oral presentation entitled "A phase II, open label, multicenter stud…
Combination of domatinostat (HDAC inhibitor) and checkpoint inhibitor avelumab (anti-PD-L1 antibody) to be investigated…
4SC AG (4SC, FSE Prime Standard: VSC) today announced that a Trial in Progress poster entitled: 1153TiP - A phase II, op…
Combination of domatinostat (HDAC inhibitor) and checkpoint inhibitor avelumab (anti-PD-L1 antibody) to be investigated…
. - Results from first nine patients include three objective responses - Two of these patients are progression-free >6…